TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

• Status: Recruiting
• Trial end date: 2024-12-31

Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact[email protected], or if a patient, your nearest participating TAPUR site (see participating centers).

********************************************************************************************* *********************************************************************************

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

********************************************************************************************* *********************************************************************************

• Phase: Phase 2

Details

• Lead Sponsor: American Society of Clinical Oncology
• Collaborators: AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme Corp.; Pfizer; Seagen Inc.
• Treatments: Afatinib; Antibodies, Monoclonal; Atezolizumab; Axitinib; Cetuximab; Crizotinib; Dasatinib; Entrectinib; Erlotinib Hydrochloride; Everolimus; Ipilimumab; Nivolumab; Olaparib; Palbociclib; Pembrolizumab; Pertuzumab; Sirolimus; Sunitinib; Talazoparib; Trastuzumab; Tucatinib; Vemurafenib